Axogen

Axogen has signed an agreement to acquire BioCircuit Technologies for $200 million in cash, thereby adding NerveTape—an FDA‑approved implant for seamless peripheral nerve repair—to its product lineup. $1 million of the purchase price will be held back pending final purchase price adjustment; closing is expected in Q4 2026. Axogen plans to finance the acquisition through a public offering of common stock announced today and expects the deal to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year after closing. After closing, Axogen will update its 2026 guidance. » More on de.investing.com

Axogen announced a public offering of 4.91 million shares at $42.50 each, expected to raise about $208.7 million before fees. The shares fell about 5.2% in premarket trading after the announcement; syndicate banks have a 30-day over-allotment option for up to 736,500 shares. The company intends to use the net proceeds mainly to pay cash for the announced acquisition of BioCircuit Technologies and for fees, working capital and capital expenditures; closing is expected on September 11, 2026. » More on de.investing.com

Axogen shares rose to a 52-week high of $51.13 and are up about 214.19% year-to-date from the 52-week low of $14.79. For Q2 2026 Axogen reported revenue of $69.7 million (+23%), beating the estimate of $67.1 million, and posted a net loss of $1.5 million ($0.03 per share); adjusted net income was $7.3 million ($0.12 per share). Analysts raised price targets or initiated coverage (H.C. Wainwright $53, Citizens $55, Truist $60), while a fair-value analysis rates the stock as potentially overvalued. » More on de.investing.com

Axogen stock traded at a 52-week high of $50.00 and is only 1% below that level, putting market capitalization at $2.67 billion. InvestingPro rates the stock as significantly overvalued despite a one-year performance of 222.92%. In Q2 2026, Axogen reported revenue of $69.7 million (+23% year-over-year) and adjusted earnings per share of $0.12, while the GAAP result showed a net loss of $1.5 million. Analysts such as H.C. Wainwright and Citizens raised price targets and maintained positive assessments due to strong growth. » More on de.investing.com

Axogen's stock hit a 52-week high of $47.09 and is currently trading at $47.11 with a market capitalization of $2.52 billion, after rising 231.91% year-to-date. In Q2 2026 Axogen reported revenue of $69.7 million (expectation $67.1 million) with adjusted EPS of $0.12, while GAAP results show a net loss of $1.5 million. Analysts raised price targets (H.C. Wainwright $53, Citizens $55) and InvestingPro currently rates the stock as overvalued but expects a return to profitability. » More on de.investing.com